MET and head and neck squamous cell carcinoma: In addition, TAVO412 also demonstrated activities in tumor types with dysregulated EGFR, c-Met, and VEGF signaling, such as head and neck squamous cell carcinoma (HNSCC) (7–9), ovarian cancer (OC) (10), hepatocellular carcinoma (HCC) (11), and small cell lung cancer (SCLC) (12).